艾姆兰蒂卡提交了FDA关键的 RefluxStopTM 文件, 这是一种治疗常见酸性反流的新设备. Implantica submits key FDA docs for RefluxStop™, a new device to treat common acid reflux.

公司已向FDA提交了其针对 RefluxStopTM的申请的第二个临床模块,该装置旨在治疗酸性反流. Implantica AG has submitted the second clinical module of its application to the FDA for RefluxStop™, a device designed to treat acid reflux. 该装置在一项为期5年的研究中显示出有希望的结果,有可能取代对胃透析性回流疾病(GERD)的标准治疗。 The device has shown promising results in a 5-year study, potentially replacing the standard treatment for gastroesophageal reflux disease (GERD). 约27%的美国成年人都患有GERD症状, Implantica旨在将这一先进技术带到最大的反回流程序市场。 With about 27% of U.S. adults experiencing GERD symptoms, Implantica aims to bring this advanced technology to the largest market for anti-reflux procedures.